BioSpace News Archive

AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), today announced the presentation of positive data from a Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, including AIM ImmunoTech Inc.’s drug candidate, Ampligen® (also known as rintatolimod), interferonα-2b, and pembrolizumab at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Orchard Therapeutics, a global gene therapy leader, announced it has reached another historic reimbursement agreement with the Italian Medicines Agency, also known as Agenzia Italiana del Farmaco, to enable access to Libmeldy® for all children with metachromatic leukodystrophy who fall within the scope of the European marketing authorization.

Pillar Biosciences Presents New Clinical Validation Data Confirming the Accuracy of Its oncoReveal ™ Dx Lung & Colon Cancer Assay in Detecting Clinically Relevant Variants.

Circle Pharma will present a poster at the American Association for Cancer Research (AACR) Annual Meeting being held April 8-13, in New Orleans, Louisiana.

ITM Announces Successful Completion of Patient Recruitment for its Phase III Trial, COMPETE, with Lead Radiotherapeutic ITM-11.

Diffusion Pharmaceuticals Inc. today announced the final participant has completed dosing in its Altitude Trial.

Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), today announced encouraging preclinical data from two pipeline programs, including in vivo combination and immunomodulation data evaluating onapristone extended release (ONA-XR), the company’s lead clinical program.

MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing peptide therapeutics with a focus on the treatment of endocrine disorders, announced the appointment of Richard B. Bartram, as Chief Financial Officer.

AnPac Bio-Medical Science Co., Ltd. announced that on April 4, 2022, the Company and Hunan Weitou Technology Co., Ltd. have signed a legally binding equity investment totaling $15 Million which will be invested in five installments over the next 30 months.

CytoImmune Therapeutics announced new preclinical data supporting the therapeutic potential of its CYTO-102 and CYTO-201 programs as treatments for patients with cancer.